Shaunna (Xiaoying) Shen, D.V.M., Ph.D.
Department of Surgery and Duke Human Vaccine Institute,
Duke University Medical Center
Title: "Antibody Measurements Indicative of Protective
Antibodies for HIV-1"
Description: The results of the RV144 efficacy trial raise the question of whether antibody responses other than traditional neutralizing antibody responses could prevent HIV-1 acquisition. While antibody responses against HIV has been extensively studied, SHIV/SIV specific antibody responses in non-human primates (NHPs) are less well characterized; and direct comparison of antibody responses against HIV Env in human and in NHP is lacking. We intend to 1) evaluate and directly compare antibody responses elicited in a human clinical trial and a NHP vaccine study that share a common HIV Env component and adjuvant, and 2) identify the properties of antigen specific antibodies (binding specificity, affinity, magnitude, breath) that can serve as markers of inhibitory antibody functions (neutralization, antibody-dependent cell-mediated cytotoxicity, virion aggregation and mucus transport inhibition).
Mentors: My mentors are Dr. Georgia Tomaras, Associate Director of Research, Duke Human Vaccine Institute, Duke University and Director, HVTN Binding Antibody Laboratory, Dr. Susan Barnett (Senior Director, Vaccines Research, Novartis), and Dr. Anthony Moody (Chief Medical Officer, Duke Human Vaccine Institute, Duke University. Dr. Tomaras is my postdoctoral research mentor and will provide guidance for the overall research plan and career development. Dr. Barnett is an expert in NHP models and vaccine immunogens/adjuvants for both human and NHP preclinical and clinical studies. Dr. Moody is an expert in HIV clinical research and directs studies in B cell biology for both human and NHP studies.